Biogen Executive and Leadership Team

November, 2026

Leadership Overview

Biogen has 9 executives leading key functions including strategy, financial oversight, research operations, commercial execution, legal compliance, medical affairs, and regional market management.

Committed to advancing neuroscience, Biogen delivers transformative therapies for patients suffering from serious neurological and neurodegenerative diseases through rigorous scientific innovation and global commercial excellence.

Leadership Roles at Biogen

  • President & Chief Executive Officer - Christopher Viehbacher
  • Chief Financial Officer - Robin Kramer
  • Chief of Staff To the Chief Financial Officer. Director - Nicholas Colafemina
  • President & Managing Director - Takatsugu Den
  • President & Head of North America - Alisha Alaimo
  • Research Chief of Staff - Evelyn Reuss
  • Chief of Staff Commercial, SYFOVRE and EMPAVELI - Kristin Melaugh
  • Chief Legal Officer - Michael Parini
  • Chief Medical Officer - Daniel Quirk
  • Christopher Viehbacher - President & Chief Executive Officer

    Christopher Viehbacher, the President & Chief Executive Officer at Biogen, directs the overarching corporate strategy and long-term vision for the organization. Overseeing the global development of therapies for neurodegenerative diseases, the President & Chief Executive Officer ensures alignment between research initiatives and commercial objectives. This leadership role involves navigating complex regulatory landscapes while driving sustainable growth across international markets. By prioritizing innovation in biologics and gene-based therapies, Christopher Viehbacher directly impacts the company's ability to address unmet patient needs. Ultimately, Viehbacher secures the competitive positioning of the firm within the global biotechnology sector, fostering a culture of scientific excellence and operational efficiency that supports the delivery of life-changing treatments to patients worldwide.
    Christopher Viehbacher

    Robin Kramer - Chief Financial Officer

    Robin Kramer, the Chief Financial Officer at Biogen, manages the fiscal health and capital allocation strategies of the enterprise. Overseeing financial planning, reporting, and investor relations, the Chief Financial Officer ensures the company maintains the necessary resources to fund high-stakes research in neuroscience. This leadership role involves optimizing cost structures to support the commercialization of therapies for multiple sclerosis and rare neurological disorders. By maintaining rigorous financial discipline, Robin Kramer directly impacts the long-term viability of the business model. Ultimately, Kramer provides the economic framework required to sustain the company's commitment to scientific discovery, ensuring that capital investments align with the strategic goals of the organization while delivering consistent value to shareholders and stakeholders across the global pharmaceutical landscape.
    Robin Kramer

    Nicholas Colafemina - Chief of Staff To the Chief Financial Officer. Director

    Nicholas Colafemina, the Chief of Staff To the Chief Financial Officer. Director at Biogen, manages the administrative and strategic priorities of the finance department. Overseeing the execution of financial initiatives, the Chief of Staff To the Chief Financial Officer. Director ensures that the office of the CFO operates with maximum efficiency. This leadership role involves synthesizing complex financial data into actionable insights for executive decision-making. By facilitating communication across the finance organization, Nicholas Colafemina directly impacts the accuracy and speed of corporate reporting. Ultimately, Colafemina supports the financial stability of the company, ensuring that the strategic vision of the CFO is implemented effectively across all departments, thereby maintaining the fiscal integrity required to support the company's ongoing investment in neuroscience and biotechnology innovation.

    Takatsugu Den - President & Managing Director

    Takatsugu Den, the President & Managing Director at Biogen, oversees the strategic operations and market expansion within the Asia-Pacific region. Directing the commercial activities and local partnerships, the President & Managing Director ensures that the company's portfolio of neurological therapies reaches patients in these critical markets. This leadership role involves adapting global strategies to meet the specific regulatory and healthcare requirements of the region. By fostering strong relationships with local stakeholders, Takatsugu Den directly impacts the growth of the company's footprint in the area. Ultimately, Den drives the regional execution of the corporate mission, ensuring that the company's commitment to neuroscience innovation is effectively translated into improved patient outcomes across diverse and rapidly evolving healthcare systems in the Asia-Pacific territory.
    Takatsugu Den

    Alisha Alaimo - President & Head of North America

    Alisha Alaimo, the President & Head of North America at Biogen, directs the commercial strategy and operational execution across the North American market. Overseeing the sales, marketing, and patient access teams, the President & Head of North America ensures that the company's therapies for multiple sclerosis and other disorders are accessible to those in need. This leadership role involves navigating the complex healthcare landscape to drive market share and revenue growth. By implementing targeted commercial initiatives, Alisha Alaimo directly impacts the company's performance in its largest market. Ultimately, Alaimo strengthens the company's competitive position, ensuring that the organization's commitment to scientific excellence is reflected in the successful delivery of high-value treatments to patients throughout the North American region.
    Alisha Alaimo

    Evelyn Reuss - Research Chief of Staff

    Evelyn Reuss, the Research Chief of Staff at Biogen, coordinates the operational workflows within the research and development division. Overseeing the integration of scientific projects, the Research Chief of Staff ensures that laboratory efforts remain synchronized with the broader mission of discovering treatments for neurodegenerative conditions. This leadership role involves facilitating communication between scientific teams and executive leadership to accelerate the pipeline of biologics. By streamlining internal processes, Evelyn Reuss directly impacts the speed and efficiency of drug development cycles. Ultimately, Reuss optimizes the research environment, allowing scientists to focus on breakthrough discoveries in neuroscience while maintaining strict adherence to project timelines and corporate objectives, thereby strengthening the company's position as a leader in the biotechnology industry.

    Kristin Melaugh - Chief of Staff Commercial, SYFOVRE and EMPAVELI

    Kristin Melaugh, the Chief of Staff Commercial, SYFOVRE and EMPAVELI at Biogen, directs the commercialization strategy for specific therapeutic assets. Overseeing the market access and launch activities for these critical products, the Chief of Staff Commercial, SYFOVRE and EMPAVELI ensures that patients gain timely access to essential treatments. This leadership role involves coordinating cross-functional teams to maximize the impact of commercial efforts in the rare disease space. By aligning marketing and sales strategies with clinical data, Kristin Melaugh directly impacts the revenue growth associated with these key therapies. Ultimately, Melaugh drives the successful market penetration of these products, ensuring that the company's commitment to addressing rare neurological disorders translates into tangible clinical outcomes and robust commercial performance within the competitive pharmaceutical market.
    Michael Parini, the Chief Legal Officer at Biogen, directs the legal and compliance framework governing the company's global operations. Overseeing intellectual property protection, regulatory adherence, and corporate governance, the Chief Legal Officer ensures that the organization operates within the highest ethical and legal standards. This leadership role involves managing complex litigation and licensing agreements that are vital to the commercialization of gene-based therapies. By mitigating legal risks, Michael Parini directly impacts the company's ability to innovate and bring new treatments to market. Ultimately, Parini safeguards the assets and reputation of the firm, providing the necessary legal foundation for the company to pursue its mission of transforming the lives of patients suffering from serious neurological diseases on a global scale.
    Michael Parini

    Daniel Quirk - Chief Medical Officer

    Daniel Quirk, the Chief Medical Officer at Biogen, leads the clinical development and medical affairs strategy for the entire product portfolio. Overseeing the design and execution of clinical trials, the Chief Medical Officer ensures that all therapies meet rigorous safety and efficacy standards before reaching patients. This leadership role involves engaging with the medical community to communicate the clinical value of treatments for spinal muscular atrophy and other disorders. By bridging the gap between scientific research and clinical practice, Daniel Quirk directly impacts the successful adoption of new therapies. Ultimately, Quirk ensures that the company's medical strategy remains patient-centric, driving the development of evidence-based solutions that address the most challenging neurological conditions in the global healthcare market.

    Explore Leadership Teams in Manufacturing

    Frequently Asked Questions Regarding Biogen Top Executives and Leadership Team

    Who leads Biogen?
    Biogen is led by Christopher Viehbacher (President & Chief Executive Officer), along with executives such as Robin Kramer (Chief Financial Officer) and Nicholas Colafemina (Chief of Staff To the Chief Financial Officer. Director).
    Who is part of Biogen’s executive team?
    The executive team of Biogen includes leaders such as Christopher Viehbacher (President & Chief Executive Officer), Robin Kramer (Chief Financial Officer), Nicholas Colafemina (Chief of Staff To the Chief Financial Officer. Director) and other senior executives.
    How many executives does Biogen have?
    Biogen has 9 executives leading key business areas.
    What roles are included in Biogen’s leadership team?
    The leadership team of Biogen includes roles such as President & Chief Executive Officer, Chief Financial Officer, Chief of Staff To the Chief Financial Officer. Director, President & Managing Director, President & Head of North America.